Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients With Relapsed or Refractory AML

Trial Profile

Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients With Relapsed or Refractory AML

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Tigecycline (Primary)
  • Indications Acute myeloid leukaemia; Bacterial infections
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 14 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 29 Jul 2013 The study is on-track for completion in Q3 2013, according to a company media release.
    • 17 Apr 2013 This study is nearing completion and data are expected this summer, according to a Stem Cell Therapeutics Corp. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top